↓ Skip to main content

Long‐term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients

Overview of attention for article published in Alimentary Pharmacology & Therapeutics, December 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 X users
f1000
1 research highlight platform

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
80 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Long‐term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients
Published in
Alimentary Pharmacology & Therapeutics, December 2016
DOI 10.1111/apt.13893
Pubmed ID
Authors

L. Angelison, S. Almer, A. Eriksson, P. Karling, U. Fagerberg, J. Halfvarson, M. Thörn, J. Björk, U. Hindorf, R. Löfberg, A. Bajor, H. Hjortswang, P. Hammarlund, O. Grip, J. Torp, J. Marsal, E. Hertervig, the Swedish Organization for the Study of Inflammatory Bowel diseases

Abstract

Real-life long-term data on infliximab treatment in ulcerative colitis are limited. To study the long-term efficacy and safety of infliximab in chronic active ulcerative colitis and possible predictors of colectomy and response were also examined. A retrospective multi-centre study of infliximab treatment in 250 patients with chronic active ulcerative colitis with inclusion criteria: age ≥18 years, ambulatory treated, steroid-dependent or intolerant and/or immunomodulator refractory or intolerant. Steroid-free clinical remission was achieved by 123/250 patients (49.2%) at 12 months and in 126/250 patients at a median follow-up of 2.9 years (50.4%). Primary response at 3 months was achieved by 190/250 (76.0%) patients and associated with a high probability of response 168/190 (88.4%) at 12 months and 143/190 (75.3%) at follow-up. Long-term rate of colectomy in primary responders was 6/190 (3.2%) at 12 months and 27/190 (14.2%) at last follow-up. Failure to achieve response at 3 months was associated with a high risk of subsequent colectomy, 29/60 (48.3%) at 12 months and 41/60 (68.3%) at follow-up. Response at 12 months was associated with a low risk of subsequent colectomy, 14/181 (7.7%) compared with non-response 19/34 (55.9%) (P < 0.0001). Non-response at 3 months was an independent predictor of subsequent colectomy (HR = 9.40, 95% CI = 5.10-17.35, P < 0.001). Concomitant azathioprine therapy did not influence outcome in terms of colectomy. Long-term efficacy of infliximab treatment in chronic active ulcerative colitis is excellent especially in patients who respond to induction treatment. Conversely, non-response at 3 months predicts a poor outcome, with a high risk of subsequent colectomy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 80 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 10 13%
Student > Master 10 13%
Researcher 8 10%
Other 6 8%
Student > Bachelor 5 6%
Other 19 24%
Unknown 22 28%
Readers by discipline Count As %
Medicine and Dentistry 40 50%
Nursing and Health Professions 3 4%
Agricultural and Biological Sciences 3 4%
Computer Science 2 3%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Other 6 8%
Unknown 24 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 August 2018.
All research outputs
#8,534,976
of 25,374,647 outputs
Outputs from Alimentary Pharmacology & Therapeutics
#2,809
of 5,633 outputs
Outputs of similar age
#145,583
of 422,428 outputs
Outputs of similar age from Alimentary Pharmacology & Therapeutics
#45
of 71 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,633 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.9. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 422,428 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.